The regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir,
an NS5A inhibitor, is advancing to a global Phase 3 program for the treatment of
hepatitis C virus (HCV). As single agents, both bemnifosbuvir and ruzasvir have
demonstrated potent pan-genotypic antiviral activity against HCV.
Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.
Hepatitis C (HCV)
Hepatitis C (HCV)
Leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology, we are discovering and developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Currently, we are focused on the development of orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV).
Updates on the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV and
other Atea news.
Global Phase 3 HCV Program Expected to Initiate in 1Q 2025 Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in Annual Net Sales The Regimen, if Approved, Should Play an Important Role in
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged Evercore, a
Atea is a clinical-stage biopharmaceutical company committed to addressing unmet medical needs through novel antiviral treatments.
Copyright © 2025 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use